Bio-Analytic Newsletter No. 4/2010
In this Issue:
- New technologies to explore biological communication
- Cancer: Patient selection by biomarker
- Disease biomarkers: what a presence in healthy controls!
- Anti-Doping Testing using highly sensitive Immuno PCR
- Interview with Prof. P. Diel (Center of Preventive Doping Research)
- Phase II study: Decision criteria for Phase III “go” or “No go”
- Study Enrollment: Ultra-sensitive screening for non-responders
- Cooperation offer: Study group profiling
- FREE WEBINAR: How to Increase Immunoassay Specificity
- Look out: Imperacer® Instrumentation
- Meet Chimera Biotech
New Publications
New technologies in affinity assays to explore biological communication (Roper & Guillo, 2010)
In their recent publication Michael Roper and Christelle Guillo from Florida State University discuss different analytical assay technologies emerged in the recent year enhancing the ability to decipher the cells language. The authors review electrophoretic, micromosaic and bead based immunoassays as well as mass spectrometric immunoassays and the ultra sensitive immunoPCR technology as tool to understand the state of certain diseases.
Recent development of molecular-targeted drugs in lung cancer (Saijo & Kenmotsu, 2010)
The authors stress the importance of patient selection in regard to lung cancer diseases. This publication highlights the recent developments of new molecular target drugs against lung cancer with special emphasis on the clinical application.
Disease biomarkers in the healthy organism (Pittsburgh Cancer Institute, 2009)
Linkov and colleagues address the reliability of biomarkers in a time where R&D as well as drug developers screen for disease markers to gain insight into progression states of various cancers. This study investigates multiple disease related proteins in serum samples over several years in healthy blood donors. More than 50% of the investigated biomarkers were present in detectable levels in more than 60% of the analyzed serum samples and they stayed stable over years in stored serum samples.
Training vs. doping: effect on biomarkers detectable and distinguishable with highly sensitive ImmunoPCR (Center of Preventive Doping Research, 2010)
This highly actual publication by Prof. Diel and his colleagues describes the effects training can have on MYOPRO concentrations compared to effect of androgens. The MYOPRO concentrations change significantly and doping becomes verifiable in blood and biopsy samples independent of the used doping agent.
Interview with Professor Diel about his research for the World Anti Doping Agency (WADA) and the used technology:
Read interview or Order interview as pdf file
Phase II biomarker study: Criteria for sensitivity and specificity for progress into phase III or early termination for futility? (Pepe et al., 2009)
Clinical studies create immense costs and it is important to determine criteria for either proceeding or dismissing a biomarker study in phase II. In this publication Prof. Pepe and her colleagues give an overview of the estimates of sensitivity and specificity to proceed with the design of phase 3 studies, but also suggests estimation procedures (including conditional-UMVUE, “naive” estimators, unconditional UMVUE and median Whitehead adjusted estimators) and stopping criteria for a reasonable early termination of a study.
Service Offers
Study enrollment: Screening for responders
(click on diagram to enlarge)
 |
 |
 |
|
||
Cytokine detection with a commonly used technology
|
|
Cytokine detection with Imperacer® technology
Check: Biomarker detection with Imperacer |
Cooperation Offer: Study group profiling
- You need a partner with know how in study enrollment?
- You want to increase the positive outcome of your clinical trials?
- You do not know the baseline levels of the biomarker you are targeting?
Contact Chimera Biotec at: info@chimera-biotec.com. We will help you with your study group profiling! Only include patient into your trial that will profit from the drug. Current FDA guidelines support patient testing prior to study enrollment (check: FDA - Screening test prior to study enrollment)
One to One Webinar: Ligand Binding Assays, how to increase immunoassay specificity
|
||
Ligand Binding Assays: how to increase immnuassay specificity
This 30minutes webinar can be ordered free of charge. The webinar focuses on ligand binding immunoassay technologies. It is designed to provide an overview on technologies, challenges and solutions as well as to discuss your projspects and challenges on a one to one basis. Order information or schedule your personal webinar directly at the speaker: punnamoottil@chimera-biotec.com |
|
Speaker: B. Punnamoottil, Ph.D., molecular neurobiologist and expert in ultra sensitive platforms. |
At a glance: Imperacer® Instrumentation
Immuno-PCR based Imperacer® Hardware
Chimera Biotec’s Imperacer® technology is based on the Immuno-PCR method. Imperacer® combines this straight-forward innovative technology with high effective antibody-DNA conjugates, robust assay protocols and an easy real-time PCR read-out. The Imperacer® instrumentation bundles are designed for cost-effective Imperacer® bioanalysis at any lab and come in customizable sizes. The package is designed to perfectly conduct Imperacer® assays in the daily laboratory routine and summarizes Chimera Biotec´s 10 year experience in Imperacer® assay development and routine bioanalysis.
Read more or contact info@chimera-biotec.com for detailed information
Meet Chimera
at the EBF 3rd Open Conference in Barcelona.
Use the opportunity to learn about the Imperacer® Technology by one of the Imperacer® experts, Dr. Mark Spengler, in the Biomarker Session.
To meet Dr. Spengler at the EBF Conference contact: spengler@chimera-biotec.com |